MX2021005685A - Metodos de inactivacion virica para la fabricacion continua de anticuerpos. - Google Patents

Metodos de inactivacion virica para la fabricacion continua de anticuerpos.

Info

Publication number
MX2021005685A
MX2021005685A MX2021005685A MX2021005685A MX2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A
Authority
MX
Mexico
Prior art keywords
viral inactivation
antibodies
continuous manufacturing
methods
inactivation methods
Prior art date
Application number
MX2021005685A
Other languages
English (en)
Inventor
Shengjiang Liu
Janice Hsiu Mei Lee
June Zou
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2021005685A publication Critical patent/MX2021005685A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta divulgación se relaciona con los métodos a usar en los virus de inactivación. Los métodos de inactivación del virus son para uso en la fabricación del proceso continuo de un agente biológico, tal como un anticuerpo e incluyen la separación de un eluato a un tratamiento ortogonal de pH bajo y detergente de manera simultánea en donde el tiempo para la inactivación vírica se reduce. Además, el detergente se puede agregar al sistema de amortiguación en el proceso de purificación para lograr el mismo efecto. Se conserva el agente biológico en cada caso de tratamiento.
MX2021005685A 2018-11-15 2019-11-14 Metodos de inactivacion virica para la fabricacion continua de anticuerpos. MX2021005685A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767652P 2018-11-15 2018-11-15
PCT/US2019/061436 WO2020102505A1 (en) 2018-11-15 2019-11-14 Viral inactivation methods for continuous manufacturing of antibodies

Publications (1)

Publication Number Publication Date
MX2021005685A true MX2021005685A (es) 2021-07-07

Family

ID=69024584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005685A MX2021005685A (es) 2018-11-15 2019-11-14 Metodos de inactivacion virica para la fabricacion continua de anticuerpos.

Country Status (14)

Country Link
EP (1) EP3880806A1 (es)
JP (1) JP7518825B2 (es)
KR (1) KR20210091709A (es)
CN (1) CN113015795B (es)
AR (1) AR117081A1 (es)
AU (1) AU2019380308A1 (es)
BR (1) BR112021006498A2 (es)
CA (1) CA3119629A1 (es)
IL (1) IL282944A (es)
MX (1) MX2021005685A (es)
PE (1) PE20211140A1 (es)
SG (1) SG11202103790WA (es)
WO (1) WO2020102505A1 (es)
ZA (1) ZA202104083B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115873810B (zh) * 2022-12-26 2024-02-09 苏州良辰生物医药科技有限公司 一种鼠白血病病毒的纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013329A1 (de) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
WO2008076371A2 (en) 2006-12-15 2008-06-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
CA2808116C (en) * 2010-07-30 2016-06-07 Pfizer Inc. Tandem purification of proteins
EP3981873A1 (en) * 2012-06-29 2022-04-13 EMD Millipore Corporation Methods for inactivating viruses during a protein purification process
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
CN105722523B (zh) 2013-11-15 2022-06-14 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
EP4234569A3 (en) * 2014-04-15 2023-10-18 Boehringer Ingelheim International GmbH Method and use for continuously inactivating a virus during manufacture of a biological product
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES

Also Published As

Publication number Publication date
TW202039836A (zh) 2020-11-01
JP2022507369A (ja) 2022-01-18
EP3880806A1 (en) 2021-09-22
SG11202103790WA (en) 2021-05-28
CN113015795A (zh) 2021-06-22
CA3119629A1 (en) 2020-05-22
CN113015795B (zh) 2024-10-01
AR117081A1 (es) 2021-07-07
PE20211140A1 (es) 2021-06-25
ZA202104083B (en) 2023-01-25
JP7518825B2 (ja) 2024-07-18
IL282944A (en) 2021-06-30
US20220002679A1 (en) 2022-01-06
BR112021006498A2 (pt) 2021-07-06
KR20210091709A (ko) 2021-07-22
WO2020102505A1 (en) 2020-05-22
AU2019380308A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
WO2016100261A3 (en) Method of treating cancer with cgamp or cgasmp
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
MX2017015666A (es) Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla).
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
EA201791443A1 (ru) Естественные киллерные клетки и их применения
BR112015022790A8 (pt) molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
WO2015048330A3 (en) On-column viral inactivation methods
MY194289A (en) Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, and Methods of use
DE602005009634D1 (de) Niedrigkonzentrations-Lösungsmittel/Detergensprozess von Immunglobulin mit Vorbehandlungsschritt
SG10201908027QA (en) Use of alkaline washes during chromatography to remove impurities
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
EA201990593A1 (ru) Непрерывный способ для снижения гетерогенности терапевтического белка
MX2021004580A (es) Compuestos de heteroarilcarboxamida de 5 miembros para el tratamiento del vhb.
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
EA202192923A1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
MX2021005685A (es) Metodos de inactivacion virica para la fabricacion continua de anticuerpos.
PH12020500176A1 (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
MX2022002231A (es) Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
BR112016027818A2 (pt) composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.
AU2017260580A1 (en) Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
EP3710025A4 (en) USE OF CYANOBACTERIA BIOMASS TO TREAT HEPATITIS B VIRUS INFECTIONS
MX2015005579A (es) Metodo para aislar synagis(r) en ausencia de benzonasa.